Close X
Attorney Spotlight

After finishing her first year as an associate at Bass, Berry & Sims, find out what advice Margaret Dodson offers to new attorneys. Read more>


Close X


Search our Experience

Experience Spotlight

On December 1, 2016, Parker Hannifin Corporation and CLARCOR Inc. announced that the companies have entered into a definitive agreement under which Parker will acquire CLARCOR for approximately $4.3 billion in cash, including the assumption of net debt. The transaction has been unanimously approved by the board of directors of each company. Upon closing of the transaction, expected to be completed by or during the first quarter of Parker’s fiscal year 2018, CLARCOR will be combined with Parker’s Filtration Group to form a leading and diverse global filtration business. Bass, Berry & Sims has served CLARCOR as primary corporate and securities counsel for 10 years and served as lead counsel on this transaction. Read more here.

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Blueprint for an IPO

Companies go public to raise capital to fuel growth, pay down debt and provide liquidity to shareholders. Although all issuers and offerings are different, the basic process of going public remains relatively constant. Blueprint for an IPO identifies the key players, details the process and identifies the obligations companies will face after going public.

Read now

The Landscape Shifts for Pharmaceutical Patents as the Supreme Court and Federal Circuit Review PTAB IPR Decisions


December 13, 2016

The pharmaceutical patent landscape is undergoing changes as the Supreme Court of the United States and the Federal Circuit review an increasing number of Patent Trial and Appeal Board inter partes review proceeding decisions. While the appellate courts give some deference to the PTAB's implementation of the America Invents Act, we are seeing more dissenting opinions and some panels are striking down the PTAB's interpretation of the AIA. During this webinar, Janelle Waack and Greg Parker will highlight relevant trends, address issues and offer insights pertinent to the pharmaceutical industry.

Topics will include:

  • Addressing Supreme Court and Federal Circuit decisions impacting IPR claim interpretation, expert testimony, amendment of claims, estoppel, burden shifting and raising new arguments in reply briefs
  • An overview of how to preserve issues in the IPR record for appeal 
  • The impact of recent Supreme Court and Federal Circuit decisions on strategies for pharmaceutical patents undergoing review at the PTAB

For more information and registration, visit the IP Counsel Exchange website.

Related Professionals

Related Services


Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.